Immunitybio (IBRX) revenue breakdown
By product, Product revenue, net is the largest at 100% of fiscal 2025 revenue, growing 698% a year over 1 years.
By region, U.S. is the largest at 100% of fiscal 2025 revenue, growing 96% a year over 6 years.
Revenue by product
Fiscal years, as Immunitybio reports them in its 10-K filings; fiscal 2025 total $113M.
| Products | 2024 | 2025 | Share |
|---|---|---|---|
| Product revenue, net | $14M | $113M | 100% |
| Other revenues | $595,000 | $306,000 | 0% |
Revenue by region
Fiscal years, as Immunitybio reports them in its 10-K filings; fiscal 2025 total $113M.
| Regions | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|---|
| U.S. | $2M | $513,000 | $373,000 | $42,000 | $31,000 | $14M | $113M | 100% |
| Europe | $205,000 | $92,000 | $561,000 | $198,000 | $591,000 | $531,000 | $278,000 | 0% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for IBRX.
Open IBRX in InvestinglyQuestions
Where does Immunitybio make its money?
In fiscal 2025, by product: Product revenue, net $113M, Other revenues $306,000.
From Immunitybio's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.